Zongertinib (HERNEXEOS) — the first oral HER2-selective tyrosine kinase inhibitor for HER2 (ERBB2)-mutant advanced NSCLC, from Boehringer Ingelheim. FDA accelerated approval Aug 8, 2025 (previously treated), expanded to first-line Feb 26, 2026. Guardant360 CDx companion diagnostic approved Jun 11, 2026.
Discover KOL Sentiment on BEAMIONLUNG1 →Design - Phase Ia/Ib open-label dose-optimization + expansion of zongertinib (Hernexeos), an oral HER2-selective TKI, in HER2 (ERBB2)-mutant advanced non-squamous NSCLC (NCT04886804).
ORR (primary) - First-line cohort confirmed ORR 76% (11% complete responses), median duration of response 15.2 months; previously-treated cohort 1 confirmed ORR 71%; confirmed intracranial ORR 47% among 30 patients with active brain metastases.
PFS - First-line median PFS 14.4 months (95% CI 11.1-NE); previously-treated cohort 1 median PFS 12.4 months (95% CI 8.2-NE).
Safety - Treatment-related adverse events were predominantly low-grade, mainly diarrhea.
Regulatory - FDA accelerated approval Aug 8, 2025 (previously treated) then first-line expansion Feb 26, 2026; Guardant360 CDx companion diagnostic approved Jun 11, 2026 (per page).
Sponsor / drug - Boehringer Ingelheim; zongertinib (Hernexeos).
Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated July 21, 2026.
Update from ASCO 2026! Get expert insights on the latest data in 𝘏𝘌𝘙2-mutant non-small cell lung cancer (NSCLC) 📺 Dr @herbloong & Dr @ipreeshagul review data from SOHO-01, Beamion LUNG-3, PRO results from the Beamion LUNG-1 trial, & advances in HER2 testing Programme https://t.co/jCjavHJSJT
Presented at #AACR25: Among patients with tumors harboring tyrosine kinase domain mutations who received zongertinib (a selective inhibitor of the HER2 tyrosine kinase), 71% had a response, and median progression-free survival was 12.4 months. Full study results: https://t.co/QEsXsFxnkP
Zongertinib is now approved for Her2+ NSCLC based off Beamion Lung-1! We had a chance to 🗣️ Her2 testing, trial, findings, AEs and sequencing w/ @JSabari Full 🗣️: ⭐️ https://t.co/Y5WjnOlts8 ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm @OncUpdates https://t.co/FWgOwiwZVc
Developments in HER2 exon 20 ins lung cancer: Boehringer & Bayer see ORRs of 60-70% with zongertinib & BAY2927088, but watch the tox! (Both molecules now in phase 3.) Via @ApexOnco from #WCLC24 -> https://t.co/tyDdvIdCGG https://t.co/b5hW7TeV7f
🎉🎉🎉We celebrate #FDA approval of #zongertinib as the first TKI in #HER2-mutant #NSCLC 🎊 🎂 🌺 🩷 👉 ORR 71% 👉 Duration of Response 14.1 months 👉 PFS 12.4 months 👉 Well-tolerated at 120mg dose 📖 In previously treated patients without prior anti-HER2 targeted therapies https://t.co/IS6XfykHSI
💊 It seems like we have two new “osimertinibs” for HER2 mutations. BAY 2927088 and Zongertinib hit the 70% response rate threshold with an acceptable toxicity profile. Already ph3 trials in 1st line HER2mut NSCLC ongoing. Competitive indication with Trastu-DXd. #WCLC24 #LCSM https://t.co/QXUErUWwig
🔥#WCLC24 Presidential 2 🎙️Dr. Gerrina Ruiter 🎯Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC #LCSM @IASLC @OncoAlert https://t.co/Q5L0yj5oBa https://t.co/zjS2IXAfre
Delighted to see our data on 1st line zongertinib in HER2 TKD mutant NSCLC pts with and without CNS mets (BEAMION-Lung01), now in @NEJM. Now FDA approved 1st line. Hoping for @MHRAgovuk & @NICEComms approvals to follow! @royalmarsdenNHS @ICR_London https://t.co/rL4vpUJOkW
🔥🚨@OncoAlert Hot Off The Press. Just published @NEJM Results of: ⭐️ #Beamion LUNG-1 phase 1a–1b of: #Zongertinib (#Oral, irreversible, HER2 #TKI) in previously treated #Patients with advanced #HER2-mutant non-small- cell #LungCancer (#NSCLC). 👇🏻 https://t.co/GAgn3eaebG https://t.co/T2Lgcb2TWm
Zongertinib in #HER2 NSCLC simultaneous publication @NEJM with #AACR25 presentation by Dr. John Heymach. In previously treated HER2 TKD mt NSCLC, RR 71%, duration of response 14.1m, mPFS 12.4m. G3 AEs in only 17% - diarrhea in 56% of pts but only 1 single case of G3 or higher. https://t.co/ZzSoeixFCy
Beamion LUNG-1 is the pivotal Phase 1b trial of zongertinib (HERNEXEOS), an oral, irreversible tyrosine kinase inhibitor that selectively targets HER2 (ERBB2) while sparing wild-type EGFR — a design intended to minimize EGFR-related toxicity. The trial enrolled patients with HER2 (ERBB2) tyrosine kinase domain-mutant advanced non-small cell lung cancer, a subset representing roughly 2–4% of NSCLC and historically associated with poor prognosis. Results supported zongertinib's FDA accelerated approval (August 2025), and on June 11, 2026 the FDA approved Guardant360 CDx as a blood-based companion diagnostic to identify eligible patients.
First-line (treatment-naïve) HER2-mutant NSCLC: confirmed ORR 76% (11% complete responses), median duration of response 15.2 months. Previously treated (cohort 1): confirmed ORR 71%. Among 30 patients with active brain metastases, the confirmed intracranial ORR was 47% (RANO-BM). Accelerated approval was based on ORR and duration of response.
First-line (treatment-naïve) cohort: median PFS 14.4 months (95% CI 11.1–NE). Previously treated cohort 1: median PFS 12.4 months (95% CI 8.2–NE). Treatment-related adverse events were predominantly low-grade (mainly diarrhea).
Zongertinib (HERNEXEOS, Boehringer Ingelheim) received FDA accelerated approval on August 8, 2025 for previously treated HER2 (ERBB2)-mutant non-squamous advanced NSCLC, then a first-line (treatment-naïve) expansion on February 26, 2026. Both are accelerated approvals based on ORR and duration of response; the confirmatory Phase III Beamion LUNG-2 trial is ongoing.
Guardant360 CDx (FDA-approved June 11, 2026) is a blood-based ctDNA assay that detects HER2 (ERBB2) tyrosine kinase domain activating mutations to identify patients eligible for zongertinib — offering a faster, less invasive alternative to tissue biopsy.
Beamion LUNG-1 (NCT04886804) is a Phase Ia/Ib open-label dose-optimization and expansion study, sponsored by Boehringer Ingelheim, of zongertinib (Hernexeos) - the first oral HER2-selective tyrosine kinase inhibitor - in patients with HER2 (ERBB2 tyrosine kinase domain)-mutant unresectable or metastatic non-squamous non-small cell lung cancer. Objective response rate and duration of response were the key endpoints supporting FDA accelerated approval.
In the first-line (treatment-naive) cohort, zongertinib produced a confirmed objective response rate of 76% (including 11% complete responses) with a median duration of response of 15.2 months and median progression-free survival of 14.4 months. In the previously-treated cohort, confirmed ORR was 71% with median PFS 12.4 months. Among 30 patients with active brain metastases, the confirmed intracranial ORR was 47%. Treatment-related adverse events were predominantly low-grade, mainly diarrhea.
Yes. The FDA granted accelerated approval to zongertinib (Hernexeos) on August 8, 2025 for adults with previously treated HER2 (ERBB2)-mutant unresectable or metastatic non-squamous NSCLC, and on February 26, 2026 expanded the accelerated approval to include first-line (treatment-naive) patients. Both are accelerated approvals based on response rate and duration of response, so continued approval may depend on confirmatory data.
Eligibility requires a HER2 (ERBB2) tyrosine kinase domain activating mutation, identified by an FDA-approved companion diagnostic. Per the page, Guardant360 CDx, a blood-based ctDNA assay, was FDA-approved on June 11, 2026 as a companion diagnostic to identify eligible patients; an FDA-approved tissue test (Oncomine Dx Target Test) is also available. Zongertinib is a HER2-selective oral TKI, distinct from HER2-directed antibody-drug conjugates such as trastuzumab deruxtecan.
Zongertinib (Hernexeos) is an oral, HER2 (ERBB2)-selective tyrosine kinase inhibitor taken by mouth, whereas trastuzumab deruxtecan (T-DXd) is an intravenous HER2-directed antibody-drug conjugate. Several KOLs on this page frame zongertinib as an oral option in the HER2-mutant NSCLC treatment landscape, including after T-DXd. Direct comparative trials would be needed to establish relative efficacy and safety.
